$LYRA News

Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC

Lyra Therapeutics Withdraws Appeal Of Nasdaq Delisting Determination; Trading In Co's Common Stock To Be Suspended At Open On March 17, 2026

Lyra Therapeutics shares are trading lower after the company announced it received a Nasdaq delisting notification.

Lyra Therapeutics shares are trading lower after the company announced it received a Nasdaq delisting notification.

Lyra Therapeutics Receives Nasdaq Delisting Notification

Lyra Therapeutics suspends further development of LYR-210

Lyra Therapeutics Provides Corporate Update

Lyra Therapeutics shares are trading lower after the company announced it decided to suspend further development of LYR-210 and a workforce reduction.

Lyra Therapeutics Transitions CEO Maria Palasis and CFO Jason Cavalier to Consulting Roles to Support Strategic Review

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Lyra Therapeutics Has Engaged SSG Capital Advisors To Assist In The Pursuit Of Strategic Alternatives

Lyra Therapeutics Decides To Suspend Further Development Of LYR-210, Its Lead Product Candidate For Chronic Rhinosinusitis, And Implement A Workforce Reduction Impacting Its Remaining 28 Employees

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Lyra Therapeutics Q3 EPS $(3.38) Beats $(5.25) Estimate, Sales $25.000K Miss $195.000K Estimate

Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Lyra Therapeutics Outlines Clinical Plan For LYR-210 Following FDA Meeting And Announces ENLIGHTEN 2 Late-Breaking Oral Presentation

HC Wainwright & Co. Reiterates Neutral on Lyra Therapeutics, Maintains $16 Price Target

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates